Lyu et al. 10.3389/fnagi.2024.

1362948

Jun, P., Zhao, H., Jung, I. C., Kwon, O., Han, C. H., Won, J., et al. (2023). Efficacy of as symptom pattern of phlegma-heat-stirring wind. J. Tradit Chin. Med. 40, 461–466.
herbal medicine treatment based on syndrome differentiation for Parkinson’s disease: doi: 10.19852/j.cnki.jtcm.2020.03.015
a systematic review and meta-analysis of randomized placebo-controlled clinical trials.
Liu, M., Yu, S., Wang, J., Qiao, J., Liu, Y., Wang, S., et al. (2020b). Ginseng protein
Front. Pharmacol. 14:1108407. doi: 10.3389/fphar.2023.1108407
protects against mitochondrial dysfunction and neurodegeneration by inducing
Jun, Y. L., Bae, C. H., Kim, D., Koo, S., and Kim, S. (2015). Korean mitochondrial unfolded protein response in Drosophila melanogaster PINK1 model of
Red Ginseng protects dopaminergic neurons by suppressing the cleavage of p35 Parkinson’s disease. J. Ethnopharmacol. 247:112213. doi: 10.1016/j.jep.2019.112213
to p25 in a Parkinson’s disease mouse model. J. Ginseng Res. 39, 148–154.
Liu, X., Zhang, J., Wang, S., Qiu, J., and Yu, C. (2017). Astragaloside IV attenuates
doi: 10.1016/j.jgr.2014.10.003
the H2O2-induced apoptosis of neuronal cells by inhibiting α-synuclein expression via
Karthikkeyan, G., Behera, S. K., Upadhyay, S. S., Pervaje, R., Prasad, T. S. K., Modi, the p38 MAPK pathway. Int. J. Mol. Med. 40, 1772–1780. doi: 10.3892/ijmm.2017.3157
P. K., et al. (2022). Metabolomics analysis highlights Yashtimadhu (Glycyrrhiza glabra
Liu, Y., Zong, X., Huang, J., Guan, Y., Li, Y., Du, T., et al. (2019). Ginsenoside Rb1
L.)-mediated neuroprotection in a rotenone-induced cellular model of Parkinson’s
regulates prefrontal cortical GABAergic transmission in MPTP-treated mice. Aging 11,
disease by restoring the mTORC1-AMPK1 axis in autophagic regulation. Phytother.
5008–5034. doi: 10.18632/aging.102095
Res. 36, 2207–2222. doi: 10.1002/ptr.7449
Liu, Z., Li, W., and Chen, H. (2020). The expert consensus on the diagnosis and
Karthikkeyan, G., Prabhu, A., Pervaje, R., Pervaje, S. K., Modi, P. K., Prasad, T. S.
treatment of integrated traditional Chinese and Western medicine in Parkinson’s
K., et al. (2021). Data on dose-dependent cytotoxicity of rotenone and neuroprotection
disease movement complications (2020) [帕 金 森 病 运 动 并 发 症 中 西 医
conferred by Yashtimadhu (Glycyrrhiza glabra L.) in an in vitro Parkinson’s disease
结 合 诊 治 专 家 共 识(2020)]. Chin. J. Neuroimmunol. Neurol. 27, 247–252.
model. Data Brief 39:107535. doi: 10.1016/j.dib.2021.107535
doi: 10.3969/j.issn.1006-2963.2020.04.001
Kim, D., Kwon, S., Jeon, H., Ryu, S., Ha, K. T., Kim, S., et al. (2018). Proteomic
Lökk, J., and Nilsson, M. (2010). Frequency, type and factors associated with
change by Korean Red Ginseng in the substantia nigra of a Parkinson’s disease mouse
the use of complementary and alternative medicine in patients with Parkinson’s
model. J. Ginseng Res. 42, 429–435. doi: 10.1016/j.jgr.2017.04.008
disease at a neurological outpatient clinic. Parkinsonism Relat. Disord. 16, 540–544.
Kim, H., Park, I., Park, K., Park, S., Kim, Y. I., Park, B. G., et al. (2022). The positive doi: 10.1016/j.parkreldis.2010.06.007
effects of poria cocos extract on quality of sleep in insomnia rat models. Int. J. Environ.
Lu, P. H., Keng, J. L., Kuo, K. L., Wang, Y. F., Tai, Y. C., and Kuo, C. Y. (2020).
Res. Public Health. 19:6629. doi: 10.3390/ijerph19116629
An Apriori algorithm-based association rule analysis to identify herb combinations for
Kim, H. J., Mason, S., Foltynie, T., Winder-Rhodes, S., Barker, R. A., Williams-Gray, treating uremic pruritus using Chinese herbal bath therapy. Evid. Based Compl. Alter.
C. H., et al. (2020). Motor complications in Parkinson’s disease: 13-year follow-up of Med. 2020:8854772 doi: 10.1155/2020/8854772
the CamPaIGN cohort. Mov. Disord. 35, 185–190. doi: 10.1002/mds.27882
Luo, X., Li, Z., Zhu, M., Xu, P., Guo, X., Wu, Z., et al. (2021). Traditional Chinese
Kim, S. R., Lee, T. Y., Kim, M. S., Lee, M. C., and Chung, S. J. (2009). Use of medicine expert consensus on diagnosis and treatment of Parkinson’s disease (Tremor
complementary and alternative medicine by Korean patients with Parkinson’s disease. and Spasm disease) [帕金森病 (颤拘病) 中医临床诊疗专家共识]. J. Trad. Chin. Med.
Clin. Neurol. Neurosurg. 111, 156–160. doi: 10.1016/j.clineuro.2008.09.011 62, 2109–2116. doi: 10.13288/j.11-2166/r.2021.23.017
Kong, W. L., Huang, Y., Qian, E., and Morris, M. J. (2020). Constipation Marsili, L., Marconi, R., and Colosimo, C. (2017). “Chapter twelve - treatment
and sleep behaviour disorder associate with processing speed and attention in strategies in early Parkinson’s disease,” in International Review of Neurobiology, eds. K.
males with Parkinson’s disease over five years follow-up. Sci. Rep. 10:19014. P. Bhatia, K. R. Chaudhuri, M. Stamelou (New York, NY: Academic Press), 345–360.
doi: 10.1038/s41598-020-75800-4
Mehndiratta, M., Garg, R. K., and Pandey, S. (2011). Nonmotor symptom complex
Kwok, J. Y. Y., Huang, T. W., Tretriluxana, J., Auyeung, M., Chau, P. H., Lin, C. C., of Parkinson’s disease–an under-recognized entity. J. Assoc. Physicians India. 59,
et al. (2021). Symptom burden and unmet support needs of patients with Parkinson’s 302–308.
disease: a cross-sectional study in asia-pacific regions. J. Am. Med. Dir. Assoc. 22,
More, S., and Choi, D. K. (2017a). Neuroprotective role of atractylenolide-I in an in
1255–1264. doi: 10.1016/j.jamda.2020.09.012
vitro and in vivo model of Parkinson’s Disease. Nutrients 9:451. doi: 10.3390/nu9050451
Lee, H. M., and Koh, S. B. (2015). Many faces of Parkinson’s disease: non-motor
More, S. V., and Choi, D. K. (2017b). Atractylenolide-I protects human SH-SY5Y
symptoms of Parkinson’s disease. J. Mov. Disord. 8, 92–97. doi: 10.14802/jmd.15003
Cells from 1-Methyl-4-Phenylpyridinium-induced apoptotic cell death. Int. J. Mol. Sci.
LeWitt, P. A., and Chaudhuri, K. R. (2020). Unmet needs in Parkinson 18:1012. doi: 10.3390/ijms18051012
disease: motor and non-motor. Parkinsonism Relat. Disord. 80, S7–s12.
Murman, D. L. (2012). Early treatment of Parkinson’s disease: opportunities for
doi: 10.1016/j.parkreldis.2020.09.024
managed care. Am. J. Managed Care 18:S183.
Li, D., Liu, Y., Wang, J., Tong, Y., and Mei, X. (2011). Basic Theory of Traditional
National Institute for Health and Care Excellence (2017). Parkinson’s Disease
Chinese Medicine, 中 医 基 础 理 论, published in Chinese. Beijing: People’s Medical
in Adults (NICE guideline NH71). London: National Institute for Health and
Publishing House.
Care Excellence
Li, H., Wang, F., Zhou, Z., Jiang, X., Li, F., Feng, Y., et al. (2022). Atractylon, a novel
National Institute of Neurological Disorders and Stroke (2004). Parkinson’s Disease:
dopamine 2 receptor agonist, ameliorates Parkinsonian like motor dysfunctions in
Challenges, Progress, and Promise. Bethesda, MD: National Institute of Neurological
MPTP-induced mice. NeuroToxicology 89, 121–126. doi: 10.1016/j.neuro.2022.01.010
Disorders and Stroke.
Li, L. C., Chen, J., Zhu, X. B., Guo, M., Chen, Q., Fang, H. M., et al. O’Sullivan, S. S., Williams, D. R., Gallagher, D. A., Massey, L. A., Silveira-
(2021). Trends of complications in patients with Parkinson’s disease in seven Moriyama, L., Lees, A. J., et al. (2008). Nonmotor symptoms as presenting complaints
major cities of China from 2016 to 2019. Int. Clin. Psychopharmacol. 36, 274–278. in Parkinson’s disease: a clinicopathological study. Mov. Disord. 23, 101–106.
doi: 10.1097/YIC.0000000000000370 doi: 10.1002/mds.21813
Li, M., Yang, H. M., Luo, D. X., Chen, J. Z., and Shi, H. J. (2016). Multi-dimensional Pan, W., Liu, J., Chen, X., Wang, Q., Wu, Y., Bai, Y., et al. (2015). A practical
analysis on Parkinson’s disease questionnaire-39 in Parkinson’s patients treated with consensus guideline for the integrative treatment of Parkinson’s disease in Shanghai,
Bushen Huoxue Granule: a multicenter, randomized, double-blinded and placebo China. Integr. Med. Int. 2, 56–62. doi: 10.1159/000435813
controlled trial. Compl. Ther. Med. 29, 116–120. doi: 10.1016/j.ctim.2016.09.008
Pang, Y., Zhu, S., and Pei, H. (2020). Pachymic acid protects against cerebral
Li, Q., Cao, M., Wei, Z., Mei, J., Zhang, Y., Li, M., et al. (2022). The protective ischemia/reperfusion injury by the PI3K/Akt signaling pathway. Metab. Brain Dis. 35,
effect of Buzhong Yiqi decoction on ischemic stroke mice and the mechanism of gut 673–680. doi: 10.1007/s11011-020-00540-3
microbiota. Front. Neurosci. 16:956620. doi: 10.3389/fnins.2022.956620
Park, W. H., Kang, S., Piao, Y., Pak, C. J., Oh, M. S., Kim, J., et al. (2015).
Li, S., and Le, W. (2021). Parkinson’s disease in traditional Chinese medicine. The Ethanol extract of Bupleurum falcatum and saikosaponins inhibit neuroinflammation
Lancet Neurol. 20:262. doi: 10.1016/S1474-442230224-8 via inhibition of NF-κB. J. Ethnopharmacol. 174, 37–44. doi: 10.1016/j.jep.2015.07.039
Li, W., Gan, J., and Liu, Z. (2021). Expert consensus on integrated traditional Parkinson’s Disease and Movement Disorders Group from Neurology Branch
Chinese and Western medicine management for sleep disorder in Parkinson’s Disease of Chinese Medical Association and Parkinson’s Disease and Movement Disorders
(2021 edition) [帕金森病睡眠障碍中西医结合管理专家共识(2021)]. J. Shanghai Group from Neurology Branch of Chinese Medical Doctor Association (2020).
Univ. Chin. Med. 35, 1–6. Guideline for diagnosis and treatment of Parkinson’s disease in China (the
Lim, H. S., Kim, Y. J., Sohn, E., Yoon, J., Kim, B. Y., Jeong, S. J., et al. (2018). fourth edition) [中 国 帕 金 森 病 治 疗 指 南(第 四 版)]. Chin. J. Neurol. 53:14.
Bojungikgi-Tang, a traditional herbal formula, exerts neuroprotective effects and doi: 10.3760/cma.j.cn113694-20200331-00233
ameliorates memory impairments in Alzheimer’s Disease-like experimental models. Pecci, C., Rivas, M. J., Moretti, C. M., Raina, G., Ramirez, C. Z., Díaz, S., et al. (2010).
Nutrients 10:1952. doi: 10.3390/nu10121952
Use of complementary and alternative therapies in outpatients with Parkinson’s disease
Lin, C. H., Chiu, H. E., Wu, S. Y., Tseng, S. T., Wu, T. C., Hung, Y. C., et al. (2021). in Argentina. Mov. Disord. 25, 2094–2098. doi: 10.1002/mds.23235
Chinese herbal products for non-motor symptoms of Parkinson’s disease in Taiwan: a
population-based study. Front. Pharmacol. 11:615657. doi: 10.3389/fphar.2020.615657 Petramfar, P., Hajari, F., Yousefi, G., Azadi, S., and Hamedi, A. (2020). Efficacy
of oral administration of licorice as an adjunct therapy on improving the symptoms
Liu, M., Hu, C., Zhang, Y., Li, Q., Zhang, Q., Fang, Y., et al. (2020a). Effect of Huatan of patients with Parkinson’s disease, A randomized double blinded clinical trial. J.
Jieyu granules in treatment of Parkinson’s disease patients with sleep disorder identified Ethnopharmacol. 247:112226. doi: 10.1016/j.jep.2019.112226

Frontiers in Aging Neuroscience 15 frontiersin.org